Next, we compared the infarct volume which was measured by MAP2 immunohistochemistry and found that RSG treatment significantly reduced the infarct volume in tPA‐treated stroke mice 1 day after MCAO (Figure 2C‐D). The gene discussed is MAP2; the disease is stroke disorder.